title: Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma.
abstract: As uveal melanoma originates in the neural crest, we aimed to explore whether somatostatin receptor (SSTR) expression is present and plays any role in these patients. Heavily pretreated metastatic uveal melanoma patients were tested with somatostatin receptor scintigraphy (SRS). Planar images of the whole body complemented by single-photon emission computed tomography on suspected sites were acquired between 4 and 24 h after an intravenous administration of 185-222 MBq (5-6 mCi) of indium-octeotride. SSTR expression in metastatic tissues was confirmed by immunohistochemistry. In seven patients, sandostatin LAR was used with therapeutic intention. Thirty white patients were tested. All had extensive metastatic disease and the median number of previous treatments was three. SRS was found to be positive in 14 (46%) of the patients, but was not related to sex, type of previous treatments, tumor site, or histological type. In 10 patients, sufficient tumor specimens were available to perform immunohistochemical staining for SSTR. All cases with positive SSTR-2A staining were also positive by SRS. Two of the seven patients who received sandostatin LAR died within a month after receiving the first dose, whereas another two (28.5%) had stable disease for more than 5 months. The median time to progression after starting sandostatin was 2.1 months (range: 0.2-5.5 months). Approximately 50% of the uveal melanoma patients with extensive metastatic disease were positive for SSR, which was consistent with immunohistochemical staining for SSTR-2A. Therapeutic approaches targeting SSTR might be beneficial in patients with metastatic uveal melanoma.
authors.affiliation: Departments of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
authors.forename: Matias E
authors.initials: ME
authors.lastname: Valsecchi
authors.forename: Misti
authors.initials: M
authors.lastname: Coronel
authors.forename: Charles M
authors.initials: CM
authors.lastname: Intenzo
authors.forename: Sung M
authors.initials: SM
authors.lastname: Kim
authors.forename: Agnieszka K
authors.initials: AK
authors.lastname: Witkiewicz
authors.forename: Takami
authors.initials: T
authors.lastname: Sato
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000556:secondary*; D008875:Middle Aged; D015282:Octreotide / Q000031:analogs & derivatives / Q000627:therapeutic use; D017481:Receptors, Somatostatin / Q000378:metabolism*; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome; D014604:Uveal Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D007205:Indium Radioisotopes; D017481:Receptors, Somatostatin; C541923:sandostatinLAR; C093733:somatostatin receptor 2; D015282:Octreotide